BioGX Xfree COVID-19 Direct RT-PCR test

Wednesday, 14 October, 2020 | Supplied by: Ngaio Diagnostics



BioGX has announced an extraction-free, direct sample addition RT-PCR test for detection of SARS-CoV-2 viral RNA in patients suspected of COVID-19.

The Xfree COVID-19 Direct RT-PCR test is a complete test in a single vial, lyophilised in the BioGX Sample-Ready format. Just add water and the patient sample, and run the test on a validated real-time PCR instrument.

The fast and simple workflow is designed to help laboratories increase their testing capacity without adding expert personnel or automation. Direct addition of patient samples without any pre-processing or extraction not only overcomes critical reagents supply issues, it should also shorten the turnaround time for results. A single 96-well plate instrument can generate up to 1500 test results every 24 h, while a 384-well plate instrument can generate up to 6000 test results.

The test is validated for use on QuantStudio 5 and CFX Touch real-time PCR instruments with the most common specimen types — nasopharyngeal and oropharyngeal (throat) swabs with collections in UTM, UVT, VTM and saline. In addition to extraction-free direct testing, the product is validated to test samples extracted with magnetic beads or silica column extraction methods.

The test can be shipped anywhere in the world, with no refrigeration required.

Online: www.ngaio.co.nz
Phone: 0011 643 548 4727
Related Products

Tecan Crescendo cDNA Synthesis for qPCR kit

Tecan has launched the Crescendo cDNA Synthesis for qPCR system to provide increased sensitivity...

Lonza HLA-typed cells

Lonza now provides an expansive selection of high-resolution human leukocyte antigen (HLA)-typed...

Bio-Rad Laboratories StarBright dyes for flow cytometry

StarBright Blue 700, StarBright Violet 440 and StarBright Violet 610 are fluorescent...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd